MX2022015629A - Uso de vibegron para tratar vejiga sobreactiva. - Google Patents

Uso de vibegron para tratar vejiga sobreactiva.

Info

Publication number
MX2022015629A
MX2022015629A MX2022015629A MX2022015629A MX2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A
Authority
MX
Mexico
Prior art keywords
vibegron
overactive bladder
treat overactive
present disclosure
relates
Prior art date
Application number
MX2022015629A
Other languages
English (en)
Inventor
Stephen C Piscitelli
Paul Mudd
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62815097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022015629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of MX2022015629A publication Critical patent/MX2022015629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación se refiere a un método de tratamiento de vejiga sobreactiva que comprende administrar por vía oral a un sujeto que lo necesita una cantidad de desde aproximadamente 60 mg hasta aproximadamente 90 mg (por ejemplo, aproximadamente 75 mg) de vibegron al día. La presente divulgación también se refiere a una composición de dosificación unitaria farmacéutica que comprende desde aproximadamente 60 mg hasta aproximadamente 90 mg (por ejemplo, aproximadamente 75 mg) de vibegron para administración oral.
MX2022015629A 2017-06-06 2019-12-04 Uso de vibegron para tratar vejiga sobreactiva. MX2022015629A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US201862637961P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
MX2022015629A true MX2022015629A (es) 2023-01-11

Family

ID=62815097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015629A MX2022015629A (es) 2017-06-06 2019-12-04 Uso de vibegron para tratar vejiga sobreactiva.

Country Status (14)

Country Link
US (2) US12102638B2 (es)
EP (2) EP3634420A1 (es)
JP (3) JP7682605B2 (es)
KR (2) KR20200012949A (es)
CN (3) CN117695286A (es)
AU (2) AU2018282104B2 (es)
BR (1) BR112019025636A2 (es)
CA (1) CA3064989A1 (es)
CL (1) CL2019003533A1 (es)
IL (2) IL317220A (es)
MX (1) MX2022015629A (es)
PH (1) PH12019502651A1 (es)
WO (1) WO2018224989A1 (es)
ZA (1) ZA202000028B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11376253B2 (en) * 2017-12-21 2022-07-05 Kyorin Pharmaceutical Co., Ltd. Agent for treating nocturnal pollakiuria
SG11202103662VA (en) * 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
PH12021551975A1 (en) * 2019-03-18 2022-07-04 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
KR20240110911A (ko) * 2020-12-22 2024-07-16 유로반트 사이언시즈 게엠베하 과민성 방광을 치료하기 위한 비베그론을 사용하여 디곡신을 모니터링하는 방법
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100506568B1 (ko) 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
ZA200503510B (en) 2002-11-07 2006-12-27 Yamanouchi Pharma Co Ltd Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
SI1620085T1 (sl) 2003-05-05 2008-12-31 Kissei Pharmaceutical Uporaba derivatov fenoksiocetne kisline za zdravljenje hiperaktivnega sečnega mehurja
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
EP2146969A1 (en) 2007-04-19 2010-01-27 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
WO2009036404A2 (en) 2007-09-13 2009-03-19 Codexis, Inc. Ketoreductase polypeptides for the reduction of acetophenones
ES2393525T3 (es) 2007-11-02 2012-12-26 Astellas Pharma Inc. Composición farmacéutica para el tratamiento de la vejiga hiperactiva
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2329014B1 (en) 2008-08-29 2014-10-22 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
CA2774992A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
US20150087832A1 (en) 2011-10-27 2015-03-26 Merck Sharp & Dohme, Corp. Process for making beta 3 agonists and intermediates
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
WO2013074650A1 (en) 2011-11-18 2013-05-23 Codexis, Inc. Biocatalysts for the preparation of hydroxy substituted carbamates
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
HRP20191546T1 (hr) 2013-03-15 2019-11-29 Merck Sharp & Dohme Postupak za pripravu beta 3 agonista i intermedijera
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20170348288A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
US20170348263A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
JP7670461B2 (ja) 2017-06-06 2025-04-30 ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング 過活動膀胱の治療のためのビベグロンの投薬
US11376253B2 (en) 2017-12-21 2022-07-05 Kyorin Pharmaceutical Co., Ltd. Agent for treating nocturnal pollakiuria
CA3098536A1 (en) 2018-05-23 2019-11-28 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
SG11202103662VA (en) 2018-12-05 2021-06-29 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
PH12021551975A1 (en) 2019-03-18 2022-07-04 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
KR20240110911A (ko) 2020-12-22 2024-07-16 유로반트 사이언시즈 게엠베하 과민성 방광을 치료하기 위한 비베그론을 사용하여 디곡신을 모니터링하는 방법
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍（ｖｉｂｅｇｒｏｎ）治療心臟衰竭之方法

Also Published As

Publication number Publication date
KR20200012949A (ko) 2020-02-05
WO2018224989A1 (en) 2018-12-13
JP2023071826A (ja) 2023-05-23
IL271164A (en) 2020-01-30
EP4410295A2 (en) 2024-08-07
CN117695287A (zh) 2024-03-15
CA3064989A1 (en) 2018-12-13
JP7682605B2 (ja) 2025-05-26
CN110869022A (zh) 2020-03-06
US20210077495A1 (en) 2021-03-18
AU2018282104B2 (en) 2024-07-11
KR20250099259A (ko) 2025-07-01
CN117695286A (zh) 2024-03-15
ZA202000028B (en) 2025-09-25
JP2020522560A (ja) 2020-07-30
EP3634420A1 (en) 2020-04-15
JP2025063196A (ja) 2025-04-15
IL317220A (en) 2025-01-01
AU2018282104A1 (en) 2019-12-12
PH12019502651A1 (en) 2020-06-08
AU2024204591A1 (en) 2024-07-18
CL2019003533A1 (es) 2020-06-26
US20260014158A1 (en) 2026-01-15
EP4410295A3 (en) 2024-10-16
US12102638B2 (en) 2024-10-01
BR112019025636A2 (pt) 2020-08-25

Similar Documents

Publication Publication Date Title
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
MX2019002265A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
BR112018068784A2 (pt) método para o tratamento de leucemia
ZA201901370B (en) Formulations for oral administration of active agents
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
BR112015012497A2 (pt) combinações farmacêuticas
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
RU2013126798A (ru) Комбинированная терапия дексаметазоном
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
MX2018001528A (es) Composicion farmaceutica que comprende sumatriptan para tratamiento de migraña.
AR118387A1 (es) Uso de vibegron para tratar la vejiga hiperactiva